The interaction between clopidogrel and proton pump inhibitors (PPI): Is there any clinical relevance?

Clinical Pharmacology: Advances and Applications

Volumn 2, Issue 1, 2010, Pages 155-162

  Sharma, Rakesh K ^a   Reddy, Hanumanth K ^a   Sharma, Rohit K ^a   Moazazi, Mathilde ^a   Elango, Lovett ^a   Singh, Vibhuti N ^b   Williams, D Keith ^a   Voelker, Donald J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Bayfront Med Center St Petersburg   (United States)

Author keywords

Acute coronary syndrome (ACS); Clopidogrel; Proton pump inhibitors (PPIS)

Indexed keywords

ACETYLSALICYLIC ACID; CGT 2168; CILOSTAZOL; CLOPIDOGREL; CLOPIDOGREL PLUS OMEPRAZOLE; CYTOCHROME P450 2C19; ESOMEPRAZOLE; FAMOTIDINE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; DUODENUM ULCER; ESOPHAGITIS; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART INFARCTION; HEART PROTECTION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; STENT THROMBOSIS; STOMACH PROTECTION; STOMACH ULCER; THROMBOCYTE AGGREGATION INHIBITION; UNSTABLE ANGINA PECTORIS;

EID: 77957157470     PISSN: None     EISSN: 11791438     Source Type: Book Series    
DOI: 10.2147/CPAA.S9807     Document Type: Article

References (46)

1. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354-362.
2. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317.
3. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
4. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
5. Sharma RK, Reddy HK, Singh VN, et al. Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag. 2009;5:965-972.
6. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118(18):1894-1909.
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-1339.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
9. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
10. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431): 331-337.
11. Moukarbel GV, Signorovitch JE, Pfeffer MA, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. 2009;30(18):2226-2232.
12. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7):e1-e157.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180(7):713-718.
14. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
15. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109(25):3171-3175.
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14): 1505-1516.
17. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363-375.
18. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153(1):66-69.
19. Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J. 2008;156:S10-S15.
20. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821-827.
21. Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84(2):236-242.
22. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
23. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116(25):2923-2932.
24. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989-997.
25. Plavix (Clopidogrel bisulphate) prescribing information. Sanofiaventis US LLC. Bristol-Myers Squibb/Sanofi-aventis Pharmaceutical Partnership, Bridgewater, NJ-08807.
26. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006;4(11):2508-2509.
27. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51(3):256-260.
28. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost. 2007;5(8):1630-1636.
29. Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009;157(1):e141-e145.
30. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52(12):1038-1039.
31. Aubert RE, Epstein RS, Teagarden JR, et al. Proton pump inhibitors' effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study. Circulation. 2008;118:S-815.
32. Stanek EJ AA, Flockhart DA. A national study of the effect of individual proton pump inhibitors on cardiovascular outcome in patients treated with clopidogrel following coronary artery stenting: the Clopidogrel Medco Outcome Study. Program and abstracts of the 32nd Annual SCAI Scientific Sessions; May 6, 2009; Las Vegas, Nevada.
33. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial. Circulation. 2008;118:S-815.
34. Bhatt DL. COGENT: a prospective, randomized, placebo controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Presented at Transcatheter Cardiovascular Therapeutics (TCT). Sep 24, 2009; San Francisco, CA.
35. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med. 2010;152(6):337-345.
36. Harjai KJ, Shenoy C, Orshaw P, Boura J, Rogers G. Six-month outcome with or without proton-pump inhibitors after successful PCI: Insights from the Gutherie PCI Registry. J Am Coll Cardiol. 2010;55:179-.
37. Kwok CS, Loke YK. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810-823.
38. US Food and Drug Administration. Early communication about ongoing safety review of Clopidogrel bisulfate (marketed as Plavix). Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationfor HeathcareProfessionals/ucm079520.htm.
39. European Medicines Agency: Public statement on possible interaction between clopidogrel and proton pump inhibitors. Accessed 5/5/2010. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/ Plavix/32895609en.pdf.
40. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9684):119-125.
41. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "Boxed Warning". A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. Jun 28.
42. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning" A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. Jul 20;56(4):321-341.
43. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119(19):2553-2560.
44. Jennings DL, Kalus JS. Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis. J Clin Pharmacol. 50(4):415-421.
45. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter doubleblind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782-786.
46. Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008;7(6):494-499.